1Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents 2000;10: 575-600.
2Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995; 64: 375-401.
3Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and Nhydroxysulfonamides inhibit both these zinc enzymes.J Med Chem 2000; 43: 3677-87.
4Webb SD, Sherratt JA, Fish RG. Mathematical modelling of tumour acidity: regulation of intracellular pH. J Theor Biol 1999; 196: 237-50.
5Gerweck LE. Tumor pH: implications for treatment and novel drug design. Semin Radiat Oncol 1998; 8: 176-82.
6Helmlinger G, Yuan E Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3:177-82.
7Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1: 241-63.
8Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE,et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95: 12596-601.
9Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A,Pastorekova S, et al. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 2000; 97: 2220-4.
10Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 1993; 13: 1549-56.
